EMBC Stock Analysis: Buy, Sell, or Hold?
EMBC - Embecta Corp. Common Stock
$3.14
0.00 (0.00%)
▲
5d:
-13.74%
30d:
-66.98%
90d:
-69.12%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 08, 2026
0d
Get Alerted When EMBC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called EMBC this week
60% bullish • 4 bearish
60% bullish • 4 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EMBC is down 13.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EMBC is down 13.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.68
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.50
63.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EMBC is currently trading at $3.14, which is considered oversold relative to its 30-day fair value range of $4.81 to $10.11. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.6) compared to its historical average (3.5). Remarkably, the market is currently pricing in an annual earnings decline of 23.4% over the next few years. This pessimistic expectation contrasts with the company's recent 82.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, EMBC is in a strong downtrend. The price is currently testing key support at $3.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+154.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EMBC is in a strong downtrend. The price is currently testing key support at $3.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+154.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.81 -
$10.11
Company Quality Score
56/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: Trading 154.8% below Wall St target ($8.00)
- WARNING: Recommendation downgraded due to -13.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.81 -
$10.11
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.09
Resistance Level
$9.43
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.56
Wall Street Target
$8.00
(+154.8%)
Revenue Growth (YoY)
-14.4%
Earnings Growth (YoY)
82.7%
Profit Margin
10.7%
Valuation Discount vs History
-23.4% cheaper
PE vs Historical
1.6 vs 3.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-23.4%
(market-implied from PE analysis)
1-Year Target
$2.83
(-10%)
2-Year Target
$2.54
(-19%)
3-Year Target
$2.29
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2→4)
$5.12
(+63%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 27.6%)
$92.04
(+2831%)
Base:
(SPY PE: 1.6, Growth: 27.6%)
$6.52
(+108%)
Bear:
(PE: 1.3, Growth: 27.6%)
$5.54
(+77%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (2x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 1.66 | Current EPS (TTM): $1.89
Bull Case
$3.67
(+17%)
Analyst growth 6.2%, PE expands to 1.8
Base Case
$3.34
(+6%)
Market implied 6.2%, PE stable at 1.7
Bear Case
$2.14
(-32%)
Severe decline -20.0%, PE contracts to 1.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.6 to 3.5
Stabilization Target:
$7.03
(+123.8%)
PE Expansion Potential:
+123.8%
Share & Embed Analysis
Last updated: May 18, 2026 5:59 AM ET
Data refreshes hourly during market hours. Next update: 6:59 AM
Data refreshes hourly during market hours. Next update: 6:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EMBC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$577 | 58 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 53 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$271 | 59 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$179 | 49 HOLD |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$91 | 64 BUY |
